ÀÏÀß·¯Ã¤¿ë°ü
ä¿ëÁ¤º¸
ÀÎÀç°Ë»ö
±³À°Á¤º¸
ÇìµåÇåÆÃ
½º¸¶Æ®Å¸¿î
ȸ¿ø¼­ºñ½º
À̷¼­ µî·Ï
ä¿ë°ø°í µî·Ï

(Sanofi/»ç³ëÇÇ) Site partnership manager

»ç³ëÇǾƺ¥Æ¼½ºÄÚ¸®¾Æ

http://www.sanofi-ave..

°ü½É±â¾÷

ÇÁ¶û½º¿¡ º»»ç¸¦ µÐ »ç³ëÇÇ ±×·ìÀº ¼¼°è ¼±µÎÀÇ ÇコÄÉ¾î ±â¾÷ÀÔ´Ï´Ù. ±¹³»¿¡¼­´Â »ç³ëÇÇ-¾Æº¥Æ¼½º ÄÚ¸®¾Æ°¡ Àü¹®ÀǾàǰ ¹× °Ç°­±â´É½Äǰ(¼¼³ëºñ½º)À» °ø±ÞÇϰí ÀÖ..  

¾÷Á¾ º´¿ø/Á¦¾à/º¹Áö ÀÚº»±Ý
±â¾÷ÇüÅ ÀϹݱâ¾÷ ¸ÅÃâÇöȲ
´ëÇ¥ÀÚ »ç¿ø¼ö
ȸ»çÁÖ¼Ò ¼­¿ï ¼­Ãʱ¸ ¹ÝÆ÷µ¿ 235
  • ÇöÀç ä¿ëÁ¤º¸¸¦ º¹»çÇÕ´Ï´Ù.
  • ÇöÀç ä¿ëÁ¤º¸¸¦ ÇÁ¸°ÆÃÇÕ´Ï´Ù.




Á÷Á¾ ¿µ¾÷°ü¸®¡¤¿µ¾÷Áö¿ø, ÆÇ¸Å¡¤¸ÅÀå°ü¸®¡¤Ä³¼Å¡¤ÇÁ·±Æ®
±Ù¹«ÇüÅ Á¤±ÔÁ÷ ä¿ëÁ÷±Þ -
¸ðÁýÀοø 0 ¸í ³ªÀÌ -
°æ·Â °æ·Â ±Þ¿©Á¶°Ç ´ç»ç±ÔÁ¤
Çз ´ëÁ¹ ÀÌ»ó Á¢¼ö±â°£ Á¢¼ö±â°£ÀÌ Áö³µ½À´Ï´Ù
 [ȨÆäÀÌÁöÁ¢¼ö]

Á¢¼ö±â°£ÀÌ Áö³µ½À´Ï´Ù

* ´ã´ç¾÷¹«
»ó¼¼Á¶°Ç

(Sanofi/»ç³ëÇÇ) Site partnership manager

¸ðÁýºÎ¹® ¹× ÀÚ°Ý¿ä°Ç

¸ðÁýºÎ¹®

¼¼ºÎ³»¿ë

Site 

partnership

Manager

The Site Partnership mission is to build strong relationships, enhance level of collaboration, 

and harness input and insights from Investigational sites to drive site performance such as

increasing the no. of patients/site, accelerating study start up and reducing overall 

development milestones through faster patient recruitment. The Site Partnership model 

will enable early CSU planning to ensure early site relationships exist ahead of future

programs and studies. These objectives will be achieved by:


-Providing Transversal Partnership: single point of contact across and in between 

 studies to improve protocol design elements, optimize clinical trial operations,

 improve site anticipation of upcoming studies, establish effective patient

 recruitment and retention plans.


-Portfolio Planning: Pro-active review at program and study level with sites to 

 provide sites with ample time to prepare for a new study, including activities that 

 promote early identification of potential study participants and reduce local competition

 for study subjects. Portfolio planning is also expected to increase the enthusiasm 

 around Sanofi programs and investigational/ post market access products.


-Establishing two way communication between Site & Sponsor: Influencing 

 Protocol design, recruitment strategies, operational efficiencies, 

 decreasing site and patient burden.  


-Site Performance: actively review metrics and mutually agree on actions, 

 explore new approaches with sites to drive operational excellence in a 

 changing environment. Exemplifies the culture and expertise to ensure 

 effective site performance and engagement


-Patient Strategy: becomes the main point of contact for patient advocacy 

 related internal/external stakeholders, overlooking the patient centric strategies

 in clinical development area.


QUALIFICATION


Language skills:

Ability to present clear messages accurately in both written and spoken English from complex information/data to all levels in the organization.


Education:

University degree in Health Sciences or equivalent


Experience & knowledge:

Minimum of 5 years of experience in clinical research


Core competencies:

Knowledge of GCP/ICH phase I-IV clinical trials

Management, leadership and communication skills, organizational, 

analytical and planning abilities, reactivity to emergent needs, able to prioritize, time management.


±Ù¹«Á¶°Ç

  • - ±Ù¹«ÇüÅ : Á¤±ÔÁ÷
  • - ±Ù¹«Áö¿ª : ¼­¿ï ¼­Ãʱ¸

ÀüÇüÀýÂ÷

  • - ¼­·ùÀüÇü > ¸éÁ¢ÀüÇü > ÇÕ°ÝÀÚ ¹ßÇ¥

Á¦Ãâ¼­·ù

  • - À̷¼­, ÀÚ±â¼Ò°³¼­ (À̷¼­¿¡ ¿¬¶ôó, Èñ¸Á¿¬ºÀ ±âÀç)

Á¢¼ö±â°£

±âŸ

  • - º´¿ªÇÊ ¶Ç´Â ¸éÁ¦ÀÚ
  • - ÇØ¿Ü¿©Çà¿¡ °á°Ý»çÀ¯°¡ ¾ø´Â ÀÚ




* ÀÔ»çÁö¿ø ½Ã Áß¿ä»çÇ×À» ²À üũÇϼ¼¿ä!

* ±Ù¹«È¯°æ
±Ù¹«Áö¿ª : ¼­¿ï
±Þ¿©Á¶°Ç : ´ç»ç±ÔÁ¤
* Á¢¼ö°³¿ä

¿À´Ã¸¶°¨

Á¢¼ö±â°£ÀÌ Áö³µ½À´Ï´Ù

¡á Á¢¼ö±â°£   ¡á ¿À´Ã   ¡á ¸¶°¨

2020. 02

  • ÀÏ
  • ¿ù
  • È­
  • ¼ö
  • ¸ñ
  • ±Ý
  • Åä
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29

2020. 03

  • ÀÏ
  • ¿ù
  • È­
  • ¼ö
  • ¸ñ
  • ±Ý
  • Åä
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
* ´ã´çÀÚ Á¤º¸
¸ðÁý±â°£ÀÌ Áö³­ ä¿ëÁ¤º¸ÀÇ °æ¿ì ´ã´çÁ¤º¸´Â °ø°³µÇÁö ¾Ê½À´Ï´Ù.
ÇöÀç ä¿ëÁ¤º¸¸¦ º¹»çÇÕ´Ï´Ù. ÇöÀç ä¿ëÁ¤º¸¸¦ ÇÁ¸°ÆÃÇÕ´Ï´Ù.

µî·Ï : 2020³â 2¿ù 24ÀÏ (¿ù) 15:16    ÃÖÁ¾¼öÁ¤ : 2020³â 2¿ù 24ÀÏ (¿ù) 15:16

º» Á¤º¸´Â »ç³ëÇǾƺ¥Æ¼½ºÄÚ¸®¾Æ ¿¡¼­ Á¦°øÇÑ ÀÚ·áÀ̸ç, ½ºÄ«¿ìÆ®Àº(´Â) ±× ³»¿ë»óÀÇ ¿À·ù ¹× Áö¿¬, ±× ³»¿ëÀ» ½Å·ÚÇÏ¿© ÃëÇØÁø Á¶Ä¡¿¡ ´ëÇÏ¿© Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. º» Á¤º¸´Â ½ºÄ«¿ìÆ®ÀÇ µ¿ÀÇ ¾øÀÌ Àç¹èÆ÷ÇÒ ¼ö ¾ø½À´Ï´Ù.

¢À ½ºÄ«¿ìÆ® ¿¡¼­´Â °ÅÁþ ±¸ÀÎ ±¤°í¿¡ ´ëÇÑ ÇÇÇØ¸¦ ÃÖ¼ÒÈ­ Çϱâ À§ÇÏ¿© ÇãÀ§ ä¿ë°ø°í¿¡ ½Å°íÁ¦µµ¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù.
°ÅÁþ±¸Àα¤°í¿¡ ´ëÇÑ ±¸Á÷ÀÚÁÖÀÇ»çÇ× ½Å°íÆ÷»ó±ÝÁ¦ ¾È³» ÇãÀ§ ä¿ë°ø°í ½Å°íÇϱâ

±Ù¹«Áö À§Ä¡ º¸±â

±Ù¹«Áö ÁÖ¼Ò

(137-040) ¼­¿ï ¼­Ãʱ¸ ¹ÝÆ÷µ¿ 235

Å©°Ôº¸±â

[ƯÁý±âȹ] ¹ý·ü»ç¹«Á÷

Á÷¾÷µ¸º¸±â

¹ý·ü»ç¹«Á÷À̶õ?º¯..

¸éÁ¢ helper

¸éÁ¢Áú¹®

Àμº ¡Ú¡Ú¡Ú¡Ú
Àû¼º ¡Ú¡Ú¡Ú¡Ú

Special Interview

½ºÆä¼ÈÀÎÅͺä
¹ý·ü »ç¹«Á÷À̶ó´Â ÀÏÀÌ ¾î¶² ÀÏÀÎÁö Àß ¸ð..